CABOMETYX® (cabozantinib) in Hepatocellular Carcinoma

This site is intended to provide healthcare professionals with information on CABOMETYX® and its therapeutic use in hepatocellular carcinoma (HCC).

Learn more

Learn more about CABOMETYX®

Indications, mechanism of action, dosing and administration and adverse event information.

Clinical data

Information on CABOMETYX® clinical data in HCC, including the CELESTIAL study.

Treatment guidelines for HCC

Current European clinical practice guidelines for the management of HCC.

References

© Ipsen Group 2019 Last updated on: December 2020. This site is published by Ipsen, which is solely responsible for the content. It is intended only for healthcare professionals from the EU – excluding France. Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-002360

Cabometyx in Europe

Learn more

Learn more about CABOMETYX®

Clinical data

Treatment guidelines for HCC

Welcome to Cabometyx.eu website. This website is intended for EU Healthcare professionals only.

Please confirm below that you are a registered healthcare professional.